論文・総説

​

・Kobayashi K., Nagai H., Matsui T., Matsuda T., Higai K. Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma. Anticancer Res. 2023;43(10):4601-4609. doi: 10.21873/anticanres.16654.

​

​

​・Uekusa S., Nemoto M., Hanai Y., Nakashin M., Miyagawa A., Yanagino S., Arita Y., Matsumoto T., Nishizawa K., Nagai H., Higai K., Matsuo K. Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study. Pharmacology​ 2023;108(5):460-468. doi: 10.1159/000531881.

​

・Nagai H., Mukozu T., Kobayashi K., Nogami A., Nagumo H., Mohri K., Watanabe G., Amanuma M., Yoshimine N., Ogino Y., Matsui D., Daido Y., Matsukiyo Y., Matsui T., Wakui N., Momiyama K., Higai K., Matsuda T. Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma. Oncology. 2023;101(1):32-40. doi: 10.1159/000527306​

​

・Nagai H., Amanuma M., Mukozu T., Kobayashi K., Nagumo H., Mohri K., Watanabe G., Yoshimine N., Ogino Y., Daido Y., Matsukiyo Y., Matsui T., Wakui N., Momiyama K., Higai K., Matsuda T., Igarashi Y. Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma. Oncology.  2023;101(10):634-644. doi: 10.1159/000531562.